A Glasgow-based research institute SB Drug Discovery has been acquired by Nottingham firm Sygnature Discovery.

The deal builds on Sygnature’s acquisition of Peak Proteins in April last year, following an investment in June 2020 by Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co.

SG Drug Discovery is providing solutions for cell line generation and drug screening in neuroscience and other therapeutic indications.

Scientific Director, Ian McPhee, said: “Our corporate values ​​and goals are a perfect fit and we are excited to become an integral part of the Sygnature group.”

Simon Hirst, CEO of Sygnature Discovery, said: “The acquisition of SB Drug Discovery is a great addition to the services Sygnature Discovery provides to its customers as we continue to become the world’s leading drug discovery partner.

“This is an exciting step forward to forge a strong partnership with a like-minded company that complements Sygnature’s existing services.”